Antonia Charchanti1, Panagiotis Kanavaros2, Efthymios Koniaris3, Agapi Kataki4, Georgios Glantzounis5, Niki J Agnantis6, Anna C Goussia6. 1. Department of Anatomy-Histology-Embryology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece; antoniacharchanti@gmail.com. 2. Department of Anatomy-Histology-Embryology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece. 3. Department of Pathology-Anatomy, Hippocration Hospital of Athens, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece. 4. Laboratory of Surgical Research, First Department of Propaedeutic Surgery, Hippocration Hospital, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece. 5. Department of Surgery, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece. 6. Department of Pathology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.
Abstract
BACKGROUND/AIM: The mechanisms underlying the contribution of the heparan sulfate proteoglycan syndecan-1 to liver tissue injury and to crucial biological processes, such as fibrogenesis, remain to be elucidated. Therefore, we investigated the immunohistochemical expression of syndecan-1 in chronic liver diseases (CLDs) and its probable role in hepatic fibrosis. MATERIALS AND METHODS: Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissue sections of biopsy material obtained from 128 patients diagnosed with CLDs. The correlation between syndecan-1 expression and the stage of fibrosis was investigated. RESULTS: According to the severity of fibrosis, cases were categorized into three groups: early fibrosis; intermediate fibrosis; advanced fibrosis. Syndecan-1 expression was significantly enhanced in advanced fibrosis compared to early (p<0.012) and intermediate (p<0.003) fibrosis. CONCLUSION: In CLDs, syndecan-1 immunohisto-chemical overexpression was found to be positively correlated with the severity of fibrosis, suggesting its probable role in hepatic fibrogenesis. Copyright
BACKGROUND/AIM: The mechanisms underlying the contribution of the heparan sulfate proteoglycan syndecan-1 to liver tissue injury and to crucial biological processes, such as fibrogenesis, remain to be elucidated. Therefore, we investigated the immunohistochemical expression of syndecan-1 in chronic liver diseases (CLDs) and its probable role in hepatic fibrosis. MATERIALS AND METHODS: Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissue sections of biopsy material obtained from 128 patients diagnosed with CLDs. The correlation between syndecan-1 expression and the stage of fibrosis was investigated. RESULTS: According to the severity of fibrosis, cases were categorized into three groups: early fibrosis; intermediate fibrosis; advanced fibrosis. Syndecan-1 expression was significantly enhanced in advanced fibrosis compared to early (p<0.012) and intermediate (p<0.003) fibrosis. CONCLUSION: In CLDs, syndecan-1 immunohisto-chemical overexpression was found to be positively correlated with the severity of fibrosis, suggesting its probable role in hepatic fibrogenesis. Copyright
Authors: K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween Journal: J Hepatol Date: 1995-06 Impact factor: 25.083
Authors: Tanyalak Parimon; Changfu Yao; David M Habiel; Lingyin Ge; Stephanie A Bora; Rena Brauer; Christopher M Evans; Ting Xie; Felix Alonso-Valenteen; Lali K Medina-Kauwe; Dianhua Jiang; Paul W Noble; Cory M Hogaboam; Nan Deng; Olivier Burgy; Travis J Antes; Melanie Königshoff; Barry R Stripp; Sina A Gharib; Peter Chen Journal: JCI Insight Date: 2019-08-08
Authors: David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal Journal: Hepatology Date: 2005-06 Impact factor: 17.425
Authors: Tünde Szatmári; Filip Mundt; Ghazal Heidari-Hamedani; Fang Zong; Elena Ferolla; Andrey Alexeyenko; Anders Hjerpe; Katalin Dobra Journal: PLoS One Date: 2012-10-29 Impact factor: 3.240
Authors: Lóránd Váncza; Katalin Karászi; Bálint Péterfia; Lilla Turiák; Katalin Dezső; Anna Sebestyén; Andrea Reszegi; Gábor Petővári; András Kiss; Zsuzsanna Schaff; Kornélia Baghy; Ilona Kovalszky Journal: Front Oncol Date: 2022-02-03 Impact factor: 6.244